MedTrace Logo

Magnetocardiography as a Diagnostic Screening Tool for Myocarditis and Other Types of Cardiomyopathy

NCT06689098 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 330

Last updated 2024-12-19

No results posted yet for this study

Summary

Accurate and rapid screening is an unmet medical need to address the increasing demand for advanced diagnostic workup in patients with suspected cardiomyopathy. Due to an overwhelmed health care system, advanced imaging is not always immediately available leading to underdiagnosis and progression of cardiomyopathies to advanced stages and sudden death. The investigator's recently demonstrated in a retrospective study that magnetocardiography (MCG) could be a suitable tool to detect inflammatory and other types of cardiomyopathies in a highly effective manner and without any safety issues. In this study, the investigator's test diagnostic accuracy of MCG prospectively.

Conditions

  • Cardiomyopathies

Interventions

DIAGNOSTIC_TEST

Magnetocardiography scan

The MCG system utilizes an array of 64 highly sensitive magnetic sensors known as superconducting quantum interference devices (SQUIDs). These sensors are placed in a shielded environment to reduce interference from external electromagnetic sources. SQUIDs capture variations in the heart's magnetic field throughout the cardiac cycle and correlate these changes with the QRS complex. To filter out electromagnetic noise, several frequency filters are applied. The measurements provide a three-dimensional view of the magnetic field, which is used to generate a composite vector representing the primary electrical axis of the heart. In assessing inflammatory cardiomyopathies, the focus is on the vector associated with the T-wave of the action potential, i.e. the vector from the T-wave beginning to the maximum (T-beg-Tmax interval). A T-wave/MCG vector T-beg-Tmax value ≥ 0.051 has been identified as indicative of pathology, as demonstrated in our previous research.

Sponsors & Collaborators

  • Berlin Institute of Health at Charité

    collaborator UNKNOWN

  • Charite University, Berlin, Germany

    collaborator OTHER

  • Biomagnetik Park Holding GmbH

    collaborator UNKNOWN

  • German Heart Institute

    lead OTHER

Principal Investigators

  • Bettina Heidecker, MD · Deutsches Herzzentrum der Charité

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-14
Primary Completion
2024-11-13
Completion
2024-12-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06689098 on ClinicalTrials.gov